42 results on '"Zhu, A.X."'
Search Results
2. Phase I/II study of neoadjuvant bevacizumab, erlotinib and 5-fluorouracil with concurrent external beam radiation therapy in locally advanced rectal cancer
3. A multicenter phase II trial of single-agent cetuximab in advanced esophageal and gastric adenocarcinoma
4. Putative role of ischemic postconditioning in a rat model of limb ischemia and reperfusion: involvement of hypoxia-inducible factor-1[alpha] expression
5. Weekly docetaxel, cisplatin, and irinotecan (TPC): results of a multicenter phase II trial in patients with metastatic esophagogastric cancer
6. Effects of spatial detail of soil information on watershed modeling
7. Abstract No. 210 KEYNOTE-937 trial in progress: adjuvant pembrolizumab for hepatocellular carcinoma and complete radiologic response after surgical resection or local ablation.
8. 1008P IMbrave150: Management of adverse events of special interest (AESIs) for atezolizumab (atezo) and bevacizumab (bev) in unresectable HCC.
9. Soil Mapping Using GIS, Expert Knowledge, and Fuzzy Logic.
10. 1017TiP KEYNOTE-937 trial in progress: adjuvant pembrolizumab in patients with hepatocellular carcinoma (HCC) and complete radiologic response after surgical resection or local ablation.
11. Clinical and Molecular Predictors of Local Failure After SBRT for Liver Metastases: A Secondary Analysis of a Prospective Phase II Trial.
12. Representing continuous spatial variation of geographic phenomena using fuzzy logic.
13. Abstract No. 347: Chemoembolization with Doxorubicin-Eluting Microspheres for Inoperable Hepatocellular Cancer: Initial Results.
14. CMR 2005: 7.06: Role of perfusion CT in monitoring anti-angiogenic response in patients with advanced hepatocellular carcinoma.
15. Comparison of automatic and patient-activated arrhythmia recordings by implantable loop recorders in the evaluation of syncope.
16. The clinical landscape of cell-free DNA alterations in 1671 patients with advanced biliary tract cancer.
17. VP10-2021: Cabozantinib (C) plus atezolizumab (A) versus sorafenib (S) as first-line systemic treatment for advanced hepatocellular carcinoma (aHCC): Results from the randomized phase III COSMIC-312 trial.
18. LBA36 Final analysis of RATIONALE-301: Randomized, phase III study of tislelizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma.
19. NRG/RTOG 1112: Randomized Phase III Study of Sorafenib vs. Stereotactic Body Radiation Therapy (SBRT) Followed by Sorafenib in Hepatocellular Carcinoma (HCC) (NCT01730937).
20. Long-Term Results of a Multi-Institutional Phase II Study of Hypofractionated Proton Beam Irradiation of Unresectable Primary Liver Tumors.
21. 1003P Baseline (BL) liver function and outcomes in patients (pts) with unresectable hepatocellular carcinoma (HCC) in KEYNOTE-240.
22. Patterns of Care and Outcomes of Definitive External Beam Radiotherapy and Radioembolization for Localized Hepatocellular Carcinoma: A Propensity Score-Adjusted Analysis.
23. O-027 - Pembrolizumab (Pembro) therapy vs best supportive care (BSC) in advanced hepatocellular carcinoma (HCC): KEYNOTE-240.
24. Patterns of Failure and Need for Biliary Intervention among Patients with Biliary Tract Cancers Treated with Definitive Surgery and Adjuvant Chemoradiation.
25. Evolutionary Analysis of Pre- and Post-treatment Molecular Diversity in Rectal Cancer Patients Receiving Neoadjuvant Chemoradiation (CRT) and a KRAS Mutation-targeted Radiosensitizer.
26. Long Term Follow-up of a Phase II Study of Autophagy Inhibition with Hydroxychloroquine (HCQ) and Preoperative (Preop) Short Course Chemoradiation (SCRT) Followed by Early Surgery for Resectable Ductal Adenocarcinoma of the Head of Pancreas (PDAC).
27. 1015TiP Ramucirumab in patients with advanced hepatocellular carcinoma and elevated alpha fetoprotein following a non-sorafenib based systemic therapy: An expansion cohort of the phase III REACH-2 study.
28. Evaluating the Impact of Combination of Nivolumab and Ipilimumab to Liver/Lung SBRT on Local Control for Colorectal and Pancreatic Cancer: A Pooled Analysis of Two Prospective Trials.
29. Hypofractionated Radiation Therapy for Unresectable/Locally Recurrent Intrahepatic Cholangiocarcinoma.
30. Circulating Tumor DNA to Predict Surgical Outcome after Neoadjuvant Chemoradiation for Borderline Resectable/Locally Advanced Pancreatic Cancer.
31. Treatment-Induced Changes in Circulating Lymphocyte Populations Associate With Survival of Patients With Hepatocellular Carcinoma (HCC) and Intrahepatic Cholangiocarcinoma (ICC) Treated With Hypofractionated Proton Therapy (HPT).
32. Change in Platelet Count and Normal Liver Dosimetry in Patients Receiving Proton Radiation Therapy for Unresectable Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma.
33. Outcomes After Liver Directed Radiation Therapy for Hepatocellular Carcinoma With Tumor Venous Thrombosis.
34. Influence of Body Mass Index (BMI) on Colorectal Cancer Mutation Status.
35. Early Response Assessment After Hypofractionated Proton Radiation Therapy for Primary Liver Tumors.
36. A Single Arm Phase 2 Study of Individualized Proton-Based Stereotactic Body Radiation Therapy (P-SBRT) of Liver Metastases.
37. Interfractional and Immobilization Related Respiratory Motion Variability for Treatment of Liver Tumors.
38. P0288 : CXCR4 inhibition reverts immunosuppressive tumor microenvironment and facilitates Anti-PD-1 immunotherapy in sorafenib-treated hepatocellular carcinoma.
39. Impact of Intravenous Contrast Enhancement Phase on Target Definition for Hepatocellular Carcinoma (HCC) and Intrahepatic Cholangiocarcinoma (IHC): Observations From Patients Enrolled on a Prospective Phase 2 Trial.
40. Tolerability of Liver Re-irradiation With Stereotactic Radiation Therapy.
41. P93 HYPOXIA UNDER SORAFENIB TREATMENT UPREGULATES SDF1a/CXCR4 RESULTING IN MYOFIBROBLAST ACTIVATION, GR1+ CELL INFILTRATION, AND DESMOPLASIA IN HEPATOCELLULAR CARCINOMA.
42. Mutational Profile of Gastroesophageal Cancer Compared to Gastric and Esophageal Cancers.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.